Samsung Seeks Third Anti-TNF Biosimilar Launch In Europe
Executive Summary
After receiving regulatory approvals in Europe for its biosimilar versions of etanercept and infliximab earlier this year, South Korea's Samsung Bioepis is now looking to add adalimumab to it and partner Biogen’s growing portfolio.
You may also be interested in...
Boehringer Ingelheim Throws Its Humira Biosimilar Hat Into The Ring
Boehringer Ingelheim is poised to submit marketing applications in the US and Europe for its biosimilar adalimumab after it showed equivalent safety and efficacy to Humira in a pivotal study.
Boehringer Ingelheim Throws Its Humira Biosimilar Hat Into The Ring
Boehringer Ingelheim is poised to submit marketing applications in the US and Europe for its biosimilar adalimumab after it showed equivalent safety and efficacy to Humira in a pivotal study.
Samsung Enters Oncology as Trastuzumab Accepted For EU Review
Samsung Bioepis's trastuzumab has become the South Korean company’s fifth biosimilar candidate to be filed for approval in Europe and also marks its planned entry into the oncology sector in the region.